By Business/Source
Currency:CHF
2024/FY
Stock NameRevenueRatio
Research, development and commercialization of biopharmaceutical products8.42M100.00%
By Country/Region
Currency:CHF
2024/FY
Stock NameRevenueRatio
Europe (Excluding Switzerland)3.21M38.18%
North America2.65M31.51%
Rest of the world1.43M16.95%
Switzerland1.12M13.35%